secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001104659-25-018223
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B
-------------------------------------------------------------------

- Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).
- Q4 gross margin 62.9% vs 51.4% a year ago; FY2024 GM 60.3%.
- Q4 net loss $53.8M ($0.41/share) vs $78.0M ($0.65) in Q4 2023; op loss $64.7M.
- Oncology tests in Q4 150,800 (+54.7% YoY); total tests 792,800 (+26.5%).
- FY2025 guidance: rev $1.87-1.95B; GM ~60-64%; positive net cash inflow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925018223/0001104659-25-018223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465925018223/tm257259d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer